Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is an American biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare genetic diseases. The company develops small molecules, biologics, and nucleic acid therapies, commercializing products including Crysvita for X-linked hypophosphatemia, Dojolvi for fatty acid oxidation disorders, and Mepsevii for MPS VII. Main revenue drivers comprise commercial sales of proprietary rare disease therapeutics alongside partner royalty revenues and milestone payments. Ultragenyx serves rare disease medical specialists, clinical genetics centers, pediatric hospitals, and rare disease patients across North America, Europe, and Latin America. The company holds a market-leading global position in precision biopharmaceutical development for rare metabolic and genetic disorders. Headquartered in Novato, California, Ultragenyx Pharmaceutical Inc is listed on the Nasdaq Stock Market.
5 of the funds FundTelligence covers report a position in Ultragenyx Pharmaceutical.
- Legal name
- Ultragenyx Pharmaceutical Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
- Exposure themes
- Gene Therapy, Genetic Medicine, Precision Medicine & Genomics
Funds holding Ultragenyx Pharmaceutical
- Schroder ISF Healthcare Innovation — Schroders · 0.7 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.03 % (partially disclosed portfolio, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)